| Literature DB >> 36119686 |
Ke-Hang Xie1, Li-Chun Chen2, Ling-Ling Liu3, Chu-Yin Su1, Hua Li1, Run-Ni Liu1, Qing-Qing Chen1, Jia-Sheng He1, Yong-Kun Ruan1, Wang-Kai He1.
Abstract
Objective: The present study aimed to determine whether residual dizziness (RD) after successful repositioning treatment in benign paroxysmal positional vertigo (BPPV) patients could be predicted by red blood cell distribution width (RDW). Materials and methods: In this study, a total of 303 BBPV patients hospitalized at the neurology department were investigated. The enrolled patients were divided into two groups after successful repositioning treatment: non-RD group included patients who were completely cured, and RD group included patients with RD. We collected data on all subjects, including general information, blood routine examination, blood biochemical examination, and magnetic resonance imaging tests.Entities:
Keywords: benign paroxysmal positional vertigo; inflammation; oxidative stress; red cell distribution width; residual dizziness
Year: 2022 PMID: 36119686 PMCID: PMC9477442 DOI: 10.3389/fneur.2022.857133
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Figure 1Flow chart for patient enrollment of the retrospective cohort study.
The clinical characteristics of the study samples.
|
|
|
| |
|---|---|---|---|
| Age (years), mean (SD) | 58.34 (10.06) | 58.34 (10.06) | — |
| Male, | 116 (58) | 58 (58) | — |
| Alcohol consumption, | 33 (17) | 16 (16) | 0.912 |
| Current smoking, | 76 (38) | 33 (33) | 0.236 |
| Hypertension, | 64 (32) | 27 (27) | 0.226 |
| Diabetes mellitus, | 42 (21) | 38 (38) | 0.002 |
| BMI, mean (SD) | 24.29 (3.42) | 24.27 (3.14) | 0.862 |
| SBP (mm Hg), mean (SD) | 136.56 (21.99) | 134.80 (22.33) | 0.360 |
| DBP (mm Hg), mean (SD) | 83.60 (12.66) | 85.21 (13.52) | 0.533 |
| WBC (109/Ul), mean (SD) | 7.16 (2.05) | 7.50 (1.98) | 0.088 |
| N/L, median (IQR) | 2.59 (2.43) | 2.71 (1.48) | 0.006 |
| HGB (109/L), mean (SD) | 140.90 (13.49) | 142.26 (15.63) | 0.464 |
| RBC(109/L), mean (SD) | 4.68 (0.56) | 4.74 (0.47) | 0.073 |
| RDW (%) median (IQR) | 12.51 (0.78) | 13.63 (1.75) | 0.000 |
| PLT (109 /L), mean (SD) | 233.37 (54.72) | 236.17 (61.27) | 0.615 |
| ALT (U/L), median (IQR) | 20.55 (9.88) | 20.51 (9.63) | 0.877 |
| TB (μmol/L), median (IQR) | 13.74 (5.97) | 12.19 (4.76) | 0.028 |
| CR (μmol/L), median (IQR) | 71.93 (16.60) | 67.31 (16.26) | 0.016 |
| CRP (mg/L) median (IQR) | 4.63 (3.80) | 5.96 (3.62) | 0.003 |
| FIB (g/L), median (IQR) | 2.64 (0.72) | 2.79 (0.79) | 0.126 |
| ALB (g/L), median (IQR) | 42.11 (3.06) | 40.85 (3.08) | 0.001 |
| UA (μmol/L), median (IQR) | 375.03 (100.88) | 351.69 (92.90) | 0.043 |
| TG (mmol/L), mean (SD) | 1.54 (0.76) | 1.66 (0.87) | 0.212 |
| TC (mmol/L), mean (SD) | 4.99 (1.06) | 5.08 (1.18) | 0.741 |
| LDL (mmol/L), mean (SD) | 3.06 (0.90) | 3.20 (1.04) | 0.379 |
| HDL (mmol/L), mean (SD) | 1.28 (0.27) | 1.25 (0.27) | 0.190 |
| FBG (mmol/L), mean (SD) | 7.27 (3.00) | 8 (1.79) | 0.000 |
| Time from onset to hospital (h), median (IQR) | 20.04 (22.33) | 21.00 (21.15) | 0.116 |
| 6-month recurrence rate, | 32 (16) | 38 (38) | 0.000 |
| Number of CRPs, median (IQR) | 1 (1–5) | 2 (1–5) | 0.000 |
|
| |||
| Antihypertensive therapy, | 52 (81) | 23 (85) | 0.452 |
| Antiglycemic therapy, | 26 (62) | 15 (40) | 0.037 |
BMI, body mass index, defined as weight in kilograms divided by the square of height in meters; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cells; N/L :Neutrophilic /lymphocytes; HGB, hemoglobin; RBC, red blood cell; RDW, red blood cell distribution width; PLT, blood platelet; ALT, alanine transaminase; TB, total bilirubin; CR, creatinine; CRP, c reactive protein; FIB, fibrinogen; ALB, albumin; UA, uric acid; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; FBG, fasting blood-glucose.
The differences were considered significant if p-value < 0.05.
p-value < 0.001.
p-value < 0.01.
p-value < 0.05.
Figure 2Correlation between serum RDW level and ALB, CR, TB, UA, CRP and N/L in RD patients.
The relationship between RDW value and number of CRPs, and recurrence of BPPV in 6 months of follow-up.
|
|
|
| |
|---|---|---|---|
|
| |||
| 1 median (SD) | 12.79 (0.69) | 13.18 (1.17) | 0.045 |
| >1– ≤ 3 median (SD) | 13.25 (0.62) | 13.82 (1.94) | 0.031 |
| >3– ≤ 5 median (SD) | 14.63 (0.77) | 15.37 (1.43) | 0.028 |
|
| |||
| 1-month median (SD) | 14.74 (1.57) | 16.01 (0.73) | 0.004 |
| 3-month median (SD) | 13.60 (1.31) | 15.61 (1.22) | 0.000 |
| 6-month median (SD) | 13.49 (1.11) | 14.90 (1.90) | 0.005 |
The differences were considered significant if p-value < 0.05.
p-value < 0.001.
p-value < 0.01.
p-value < 0.05.
Figure 3The relationship between RDW value and number of CRPs, recurrence of BPPV in 6 months of follow-up.
Risk factors for RD using multiple logistic regression.
|
|
|
|
|
|---|---|---|---|
| RDW | 2.615 | 1.875–3.648 | 0.000 |
| CR | 1.048 | 1.018–1.079 | 0.002 |
| ALB | 0.847 | 0.770–0.931 | 0.001 |
| TB | 1.082 | 1.022–1.145 | 0.007 |
| GLU | 1.327 | 1.143–1.542 | 0.000 |
The differences were considered significant if p-value < 0.05.
p-value < 0.001.
p-value < 0.01.
p-value < 0.05.
Figure 4ROC curve to establish the sensitivity and specificity of RDW levels to predict the risk of RD and recurrence after BPPV.